News
Peptomyc announces the beginning of a Phase 2 clinical trial of OMO-103 in advanced osteosarcoma
Peptomyc SL, a clinical-stage biotech company focused on developing new mini-protein therapeutics targeting MYC, the most dysregulated oncogene in human cancer, announced the approval of
Accure Therapeutics partner Oculis reached positive phase 2 results for lead neuroprotective therapy
Accure Therapeutics, a private translational neuroscience R&D company, today announces the positive results of ACUITY, a phase 2 trial involving a drug candidate that was
Peptomyc announces Research IND Approval for Innovative Window of Opportunity Trial in Collaboration with OHSU Knight Cancer Institute, Portland, Oregon, USA, in PDAC patients
Peptomyc is pleased to announce the approval of a Research Investigational New Drug (IND) application for a groundbreaking Window of Opportunity trial in collaboration with
deepull receives FDA Breakthrough Device Designation for its UllCORE Bloodstream Infection Test
deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification, announced today that it has received Breakthrough Device Designation from the U.S. Food
INBRAIN Neuroelectronics Raises $50M Series B to Advance Graphene-Based Brain-Computer Interface Technology
INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company developing graphene-based neural technologies, today announced the close of a $50 million Series B financing round. The
Inbiomotion and SPA – Società Prodotti Antibiotici (SPA Farma) sign an exclusive agreement for MAF Test in Italy
SPA Farma, a leading pharmaceutical company of innovative healthcare products and diagnostic tools, and Inbiomotion, proprietors of MAF Test for identifying high risk early-stage breast
